21 – 30 of 1481
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Health-promoting text messages to patients with hypertension—A randomized controlled trial in Swedish primary healthcare
- Contribution to journal › Article
-
Mark
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
- Contribution to journal › Article
-
Mark
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease
- Contribution to journal › Article
-
Mark
Updated appropriate use criteria for amyloid and tau PET : A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
- Contribution to journal › Scientific review
-
Mark
Plasma p-tau217 in Alzheimer's disease : Lumipulse and ALZpath SIMOA head-to-head comparison
- Contribution to journal › Article
-
Mark
The impact of disease activity and interferon-α on the nervous system in systemic lupus erythematosus
- Contribution to journal › Article
-
Mark
Beware of diffusion models for synthesizing medical images—a comparison with GANs in terms of memorizing brain MRI and chest x-ray images
- Contribution to journal › Article
-
Mark
evoke and evoke+ : design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
- Contribution to journal › Article
-
Mark
Benchmarking Alzheimer’s disease prediction : personalised risk assessment using polygenic risk scores across various methodologies and genome-wide studies
- Contribution to journal › Article
-
Mark
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
- Contribution to journal › Scientific review
